Drug Trial Radar · NCT02058368
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
Last checked: Nov 20, 2026Latest source record: Apr 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
607
Actual
Start
Feb 10, 2014
Primary completion
Mar 3, 2017
Study completion Mar 3, 2017
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin monotherapy for the improvement of symptoms and health outcomes in an at risk population of benign prostatic hyperplasia (BPH) clinical progression including older men (\>=50 years), with moderate-severe symptoms of BPH, enlarged prostates (\>=30 cubicentimeter \[cc\]) and prostate specific antigen (PSA) \>= 1.5 nanograms per milliliter (ng/mL). Each subject who met the eligibility criteria at screening will enter a four-week single-blind, placebo run-in period following which each subject will be randomised into a 2 year double-blind treatment phase. The total study duration for each subject will be up to 110 weeks.
Conditions
- Prostatic Hyperplasia
Interventions
Dutasteride 0.5mg capsulesDrug
Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Dutasteride placebo capsulesDrug
Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Tamsulosin 0.2mg tabletsDrug
Commercially available tamsulosin 0.2mg tablets will be supplied.
Disintegrating placebo tamsulosin tabletDrug
Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 MonthsTime frame: Baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months
Locations
46 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Xiame, Fujian, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Wuhan, Hubei, China
GSK Investigational Site
Suzhou, Jiangsu, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Hangzhou, Zhejiang, China
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Hyōgo, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Ōita, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Saitama, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Yamanashi, Japan
GSK Investigational Site
Busan, South Korea
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Gwangju, South Korea
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Jeonju, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Chiayi City, Taiwan
GSK Investigational Site
Hualien City, Taiwan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.